Related Experiment Videos
Does fingolimod in multiple sclerosis patients cause macular edema?
Kiran Turaka1, Joseph Shepard Bryan
1Associated Retina Consultants Ltd, 7600 N 15th Street, Phoenix, AZ 85020, USA. keen_268@yahoo.com
Journal of Neurology
|January 11, 2012
Summary
Fingolimod, used for multiple sclerosis (MS), can cause reversible macular edema (ME). This case report shows ME resolved after discontinuing the drug and using topical corticosteroids.
Area of Science:
- Ophthalmology
- Neurology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a central nervous system demyelinating disease often causing optic neuritis.
- Fingolimod is an immunosuppressive therapy used to reduce MS exacerbations.
Observation:
- A patient with relapsing-remitting MS on fingolimod experienced acute vision loss.
- Ophthalmological examination revealed macular edema (ME) in the affected eye, confirmed by fluorescein angiography and optical coherence tomography (OCT).
Findings:
- Macular edema (ME) developed as a potential side effect of fingolimod treatment.
- Cessation of fingolimod combined with topical corticosteroid therapy led to complete resolution of the ME.
Implications:
- This case highlights that fingolimod-induced macular edema is a reversible side effect.
- Optical coherence tomography (OCT) can monitor the resolution of fingolimod-induced macular edema.
Related Concept Videos
01:21Cytotoxic Edema: Pathophysiology
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...